|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
DE122007000001I1
(de)
|
1999-01-14 |
2007-06-28 |
Amylin Pharmaceuticals Inc |
Neue exendin agonist Formulierungen und deren Verabreichung
|
|
EP1658856B1
(en)
|
1999-01-14 |
2010-03-17 |
Amylin Pharmaceuticals, Inc. |
Exendins for glucagon suppression
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
EA003922B1
(ru)
|
1999-05-17 |
2003-10-30 |
Конджачем, Инк. |
Продолжительно действующие инсулинотропные пептиды
|
|
US6506724B1
(en)
*
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
EP1076066A1
(en)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
HU229208B1
(en)
|
2000-06-16 |
2013-09-30 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
|
BR0116024A
(pt)
|
2000-12-07 |
2005-12-13 |
Lilly Co Eli |
Proteìna de fusão heteróloga e uso da mesma
|
|
MXPA03005388A
(es)
|
2000-12-14 |
2003-09-25 |
Amylin Pharmaceuticals Inc |
Peptido yy y agonistas de peptido yy para el tratamiento de desordenes metabolicos.
|
|
EP1980572A1
(en)
|
2001-02-16 |
2008-10-15 |
ConjuChem Biotechnologies Inc. |
Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
|
|
CN1162446C
(zh)
*
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
WO2003020201A2
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
|
JP2005508360A
(ja)
|
2001-10-19 |
2005-03-31 |
イーライ・リリー・アンド・カンパニー |
Ｇｌｐ−１およびインスリンの二相混合物
|
|
US20050148497A1
(en)
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
|
ATE432289T1
(de)
|
2002-07-04 |
2009-06-15 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
|
MXPA05003335A
(es)
|
2002-10-02 |
2005-07-05 |
Zealand Pharma As |
Compuestos de exendina-4 estabilizados.
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
WO2005000222A2
(en)
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
AU2005211776B2
(en)
|
2004-02-11 |
2012-02-02 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
WO2006083254A1
(en)
|
2004-02-11 |
2006-08-10 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US20060094652A1
(en)
|
2004-02-11 |
2006-05-04 |
Levy Odile E |
Hybrid polypeptides with selectable properties
|
|
EP2314615A3
(en)
|
2004-10-08 |
2011-07-20 |
Amylin Pharmaceuticals, Inc. |
Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them
|
|
CN101094689B
(zh)
|
2004-11-01 |
2013-06-12 |
安米林药品有限责任公司 |
治疗肥胖以及肥胖相关疾病和病症的方法
|
|
NZ555464A
(en)
*
|
2004-12-02 |
2010-03-26 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
|
BRPI0518559A2
(pt)
|
2004-12-13 |
2008-11-25 |
Amylin Pharmaceuticals Inc |
motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
EA011653B1
(ru)
|
2005-02-11 |
2009-04-28 |
Амилин Фармасьютикалз, Инк. |
Аналоги и гибридные полипептиды gip с избираемыми свойствами
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
DK1888103T3
(da)
|
2005-04-11 |
2012-04-23 |
Amylin Pharmaceuticals Inc |
Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
|
|
EP1922336B1
(en)
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
|
EP2332526A3
(en)
|
2005-10-21 |
2011-10-12 |
Novartis AG |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
|
CN102274557B
(zh)
|
2006-08-09 |
2014-12-03 |
精达制药公司 |
渗透性递送系统和活塞组件
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
EP2114437A2
(en)
|
2006-10-16 |
2009-11-11 |
ConjuChem Biotechnologies Inc. |
Modified corticotropin releasing factor peptides and uses thereof
|
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
|
DK2157967T3
(da)
|
2007-04-23 |
2013-04-08 |
Intarcia Therapeutics Inc |
Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf
|
|
WO2008148839A2
(en)
|
2007-06-08 |
2008-12-11 |
Ascendis Pharma As |
Long-acting polymeric prodrugs of exendin
|
|
JP2010538069A
(ja)
*
|
2007-09-07 |
2010-12-09 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
エキセンディン−４およびエキセンディン−３の類似体
|
|
US8343140B2
(en)
|
2008-02-13 |
2013-01-01 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
JP2011517561A
(ja)
|
2008-03-31 |
2011-06-16 |
グラクソ グループ リミテッド |
薬物融合体および複合体
|
|
EP2303313B1
(en)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendins to lower cholestrol and triglycerides
|
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
PT3228320T
(pt)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combinação de uma insulina e de um agonista do glp-1
|
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
NZ595344A
(en)
|
2009-03-27 |
2013-09-27 |
Glaxo Group Ltd |
Drug fusions and conjugates
|
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
MX2012001399A
(es)
|
2009-07-31 |
2012-03-21 |
Sanofi Aventis Deutschland |
Profarmacos que comprenden un conjugado de insulina-conector.
|
|
UA108475C2
(uk)
|
2009-07-31 |
2015-05-12 |
Санофі-Авентіс Дойчланд Гмбх |
Композиція інсуліну тривалої дії
|
|
LT2462246T
(lt)
|
2009-09-28 |
2017-11-27 |
Intarcia Therapeutics, Inc |
Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
|
|
CN104147611A
(zh)
|
2009-09-30 |
2014-11-19 |
葛兰素集团有限公司 |
具有延长的半衰期的药物融合体和缀合物
|
|
TR201809460T4
(tr)
|
2009-11-13 |
2018-07-23 |
Sanofi Aventis Deutschland |
Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
|
|
JP5973918B2
(ja)
|
2009-11-13 |
2016-08-23 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
|
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
|
WO2011133948A2
(en)
|
2010-04-22 |
2011-10-27 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
|
TWI523659B
(zh)
|
2010-04-27 |
2016-03-01 |
西蘭製藥公司 |
肽結合物
|
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
|
JP6199186B2
(ja)
|
2010-08-30 |
2017-09-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
JP6121330B2
(ja)
|
2010-09-28 |
2017-04-26 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続時間が増した改変ポリペプチド
|
|
JP2014504588A
(ja)
|
2010-12-22 |
2014-02-24 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
US9580471B2
(en)
|
2011-03-01 |
2017-02-28 |
Synergy Pharmaceuticals, Inc. |
Process of preparing guanylate cyclase C agonists
|
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
CN104271588B
(zh)
|
2011-07-08 |
2017-10-10 |
安米林药品有限责任公司 |
具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
|
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
US20130096059A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
|
WO2013050379A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
|
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
|
EP2849775A1
(en)
|
2012-05-16 |
2015-03-25 |
Glaxo Group Limited |
Polypeptide loaded poca nanoparticles for oral administration
|
|
WO2013170636A1
(zh)
|
2012-05-18 |
2013-11-21 |
爱德迪安（北京）生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
|
US10442847B2
(en)
|
2012-07-23 |
2019-10-15 |
Zealand Pharma A/S |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
EP2934569A1
(en)
|
2012-12-21 |
2015-10-28 |
Sanofi |
Exendin-4 derivatives
|
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
WO2014145718A2
(en)
|
2013-03-15 |
2014-09-18 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
|
MX2015015249A
(es)
|
2013-05-02 |
2016-02-09 |
Glaxosmithkline Ip Dev Ltd |
Peptidos terapeuticos.
|
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
BR112016008115B1
(pt)
|
2013-10-17 |
2024-03-12 |
Boehringer Ingelheim International Gmbh |
Análogos de glucagon acilados
|
|
BR112016009995B1
(pt)
|
2013-11-06 |
2023-04-18 |
Zealand Pharma A/S |
Compostos agonistas triplos glucagon-glp-1-gip
|
|
BR112016009889B1
(pt)
|
2013-11-06 |
2023-11-28 |
Zealand Pharma A/S |
Análogo do gip, composição farmacêutica compreendendo um análogo do gip, ou um sal farmaceuticamente aceitável do mesmo, e seu uso
|
|
CN105934257B
(zh)
|
2013-12-06 |
2020-10-09 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
MX2016008979A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
|
|
BR112016015851A2
(pt)
|
2014-01-09 |
2017-08-08 |
Sanofi Sa |
Formulações farmacêuticas estabilizadas de insulina aspart
|
|
CN105899191B
(zh)
|
2014-01-09 |
2020-06-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
US9708272B2
(en)
|
2014-08-29 |
2017-07-18 |
Tes Pharma S.R.L. |
Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
|
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
BR112017008659A2
(pt)
|
2014-10-29 |
2018-01-30 |
Zealand Pharma As |
?métodos e compostos de agonista de gip?
|
|
CA2970200A1
(en)
|
2014-12-12 |
2016-06-16 |
Sanofi-Aventis Deutschland Gmbh |
Insulin glargine/lixisenatide fixed ratio formulation
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
|
CN113598842A
(zh)
|
2015-06-03 |
2021-11-05 |
因塔西亚制药公司 |
植入物放置和移除系统
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
US10294303B2
(en)
|
2015-12-23 |
2019-05-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
|
EP3458084B1
(en)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
RU2019114228A
(ru)
|
2016-10-14 |
2020-11-16 |
Тес Фарма С.Р.Л. |
ИНГИБИТОРЫ ДЕКАРБОКСИЛАЗЫ ПОЛУАЛЬДЕГИДА α-АМИНО-β-КАРБОКСИМУКОНОВОЙ КИСЛОТЫ
|
|
CA3040906A1
(en)
|
2016-10-20 |
2018-04-26 |
Peptron, Inc. |
Methods of delivering a neuroprotective polypeptide to the central nervous system
|
|
EP3551202B1
(en)
|
2016-12-06 |
2024-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
|
EP3565580B1
(en)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
US20210087286A1
(en)
|
2017-06-20 |
2021-03-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
|
CA3096493A1
(en)
|
2018-04-10 |
2019-10-17 |
Sanofi-Aventis Deutschland Gmbh |
Method for cleavage of solid phase-bound peptides from the solid phase
|
|
CA3096495A1
(en)
|
2018-04-10 |
2019-10-17 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatide synthesis with capping
|
|
KR20210111248A
(ko)
|
2018-11-20 |
2021-09-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
|
|
AU2020233876A1
(en)
|
2019-03-08 |
2021-09-23 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|